Blau Farmacêutica S.A
Blau Farmacêutica S.A., a pharmaceutical company provides drug products in Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and the United States. Its products cover various areas, such as immunology, hematology, oncology, nephrology, infectology, and anesthesiology. The company offers uterine stimulator, antirheumatic, anaesthetics, antibiotics, feminine health care, biopharmaceutical… Read more
Blau Farmacêutica S.A (BLAU3) - Net Assets
Latest net assets as of September 2025: R$2.33 Billion BRL
Based on the latest financial reports, Blau Farmacêutica S.A (BLAU3) has net assets worth R$2.33 Billion BRL as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (R$3.62 Billion) and total liabilities (R$1.29 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | R$2.33 Billion |
| % of Total Assets | 64.48% |
| Annual Growth Rate | 37.04% |
| 5-Year Change | 871.64% |
| 10-Year Change | 2469.61% |
| Growth Volatility | 179.61 |
Blau Farmacêutica S.A - Net Assets Trend (2013–2024)
This chart illustrates how Blau Farmacêutica S.A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Blau Farmacêutica S.A (2013–2024)
The table below shows the annual net assets of Blau Farmacêutica S.A from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | R$2.15 Billion | +7.79% |
| 2023-12-31 | R$2.00 Billion | +9.75% |
| 2022-12-31 | R$1.82 Billion | +11.20% |
| 2021-12-31 | R$1.63 Billion | +638.62% |
| 2020-12-31 | R$221.34 Million | -16.71% |
| 2019-12-31 | R$265.76 Million | +18.99% |
| 2018-12-31 | R$223.33 Million | +61.44% |
| 2017-12-31 | R$138.34 Million | +41.90% |
| 2016-12-31 | R$97.49 Million | +16.48% |
| 2015-12-31 | R$83.70 Million | +3.86% |
| 2014-12-31 | R$80.58 Million | +19.99% |
| 2013-12-31 | R$67.16 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Blau Farmacêutica S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2838.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | R$899.32 Million | 41.56% |
| Common Stock | R$1.32 Billion | 60.84% |
| Other Comprehensive Income | R$-9.05 Million | -0.42% |
| Total Equity | R$2.16 Billion | 100.00% |
Blau Farmacêutica S.A Competitors by Market Cap
The table below lists competitors of Blau Farmacêutica S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Rorze Systems Corporation
KQ:071280
|
$48.46 Million |
|
Soken Chemical & Engineering Co. Ltd
MU:SOQ
|
$48.50 Million |
|
Melhus Sparebank
OL:MELG
|
$48.50 Million |
|
MedPeerInc
PINK:MDPEF
|
$48.50 Million |
|
Zeotech Ltd
AU:ZEO
|
$48.41 Million |
|
Burcelik Bursa Celik Dokum Sanayi AS
IS:BURCE
|
$48.39 Million |
|
HMS Bergbau AG
XETRA:HMU
|
$48.39 Million |
|
Infant Bacterial Therapeutics AB (publ)
ST:IBT-B
|
$48.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Blau Farmacêutica S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,001,464,000 to 2,163,989,000, a change of 162,525,000 (8.1%).
- Net income of 217,206,000 contributed positively to equity growth.
- Dividend payments of 56,108,000 reduced retained earnings.
- Share repurchases of 1,797,000 reduced equity.
- Other comprehensive income increased equity by 7,567,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | R$217.21 Million | +10.04% |
| Dividends Paid | R$56.11 Million | -2.59% |
| Share Repurchases | R$1.80 Million | -0.08% |
| Other Comprehensive Income | R$7.57 Million | +0.35% |
| Other Changes | R$-4.34 Million | -0.2% |
| Total Change | R$- | 8.12% |
Book Value vs Market Value Analysis
This analysis compares Blau Farmacêutica S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.82x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 24.77x to 0.82x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | R$0.40 | R$9.94 | x |
| 2014-12-31 | R$0.48 | R$9.94 | x |
| 2015-12-31 | R$0.42 | R$9.94 | x |
| 2016-12-31 | R$0.56 | R$9.94 | x |
| 2017-12-31 | R$0.79 | R$9.94 | x |
| 2018-12-31 | R$1.27 | R$9.94 | x |
| 2019-12-31 | R$1.76 | R$9.94 | x |
| 2020-12-31 | R$1.26 | R$9.94 | x |
| 2021-12-31 | R$9.12 | R$9.94 | x |
| 2022-12-31 | R$10.16 | R$9.94 | x |
| 2023-12-31 | R$11.26 | R$9.94 | x |
| 2024-12-31 | R$12.18 | R$9.94 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Blau Farmacêutica S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.04%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.38%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 1.58x
- Recent ROE (10.04%) is below the historical average (41.02%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 25.59% | 5.60% | 1.15x | 3.96x | R$9.26 Million |
| 2014 | 23.61% | 5.64% | 1.14x | 3.67x | R$9.73 Million |
| 2015 | 27.55% | 6.01% | 1.26x | 3.62x | R$14.69 Million |
| 2016 | 33.17% | 7.50% | 1.36x | 3.24x | R$22.58 Million |
| 2017 | 74.55% | 16.70% | 1.69x | 2.65x | R$89.29 Million |
| 2018 | 55.19% | 15.76% | 1.32x | 2.66x | R$100.92 Million |
| 2019 | 75.35% | 20.48% | 1.32x | 2.78x | R$173.66 Million |
| 2020 | 114.90% | 21.52% | 0.93x | 5.75x | R$232.20 Million |
| 2021 | 19.88% | 23.80% | 0.59x | 1.42x | R$161.59 Million |
| 2022 | 19.94% | 25.83% | 0.56x | 1.37x | R$181.15 Million |
| 2023 | 12.48% | 18.20% | 0.45x | 1.53x | R$49.66 Million |
| 2024 | 10.04% | 12.38% | 0.51x | 1.58x | R$807.10K |
Industry Comparison
This section compares Blau Farmacêutica S.A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $266,373,500
- Average return on equity (ROE) among peers: 43.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Blau Farmacêutica S.A (BLAU3) | R$2.33 Billion | 25.59% | 0.55x | $48.45 Million |
| Hypera S.A (HYPE3) | $40.30 Million | 76.92% | 5.39x | $1.04 Billion |
| Ouro Fino Saúde Animal Participações S.A (OFSA3) | $492.45 Million | 9.40% | 0.77x | $32.46 Million |